Media coverage
10
Media coverage
Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera Media name/outlet Business Wire Country/Territory United States Date 23/05/23 URL www.businesswire.com/news/home/20230523005317/en/NCCN-Clinical-Practice-Guidelines-in-Oncology-Updated-to-Recommend-BESREMi%C2%AE-ropeginterferon-alfa-2b-njft-as-a-Preferred-Intervention-for-Polycythemia-Vera/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT Persons John Mascarenhas Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera; BESREMi moved to preferred intervention based on superior efficacy, safety and evidence for both Media name/outlet Business Wire Country/Territory United States Date 23/05/23 URL metabase.moreover.com/noarticleurl?type=psh&lni=6898-Y5C1-JBG1-81SK-00000-00 Persons John Mascarenhas Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera Media name/outlet Yahoo! Finance Country/Territory United States Date 23/05/23 URL https://finance.yahoo.com/news/nccn-clinical-practice-guidelines-oncology-120000941.html Persons John Mascarenhas Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera Media name/outlet ADVFN US Country/Territory United States Date 23/05/23 URL https://www.advfn.com/p.php?pid=nmona&article=91136536 Persons John Mascarenhas Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera Media name/outlet MarketScreener.com Country/Territory United States Date 23/05/23 URL https://www.marketscreener.com/quote/stock/PHARMAESSENTIA-CORPORATIO-26902371/news/NCCN-Clinical-Practice-Guidelines-in-Oncology-Updated-to-Recommend-BESREMi-ropeginterferon-alfa-2b-43924062/ Persons John Mascarenhas Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera Media name/outlet Le Lezard.com Country/Territory Canada Date 23/05/23 URL https://www.lelezard.com/en/news-20912394.html Persons John Mascarenhas Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera Media name/outlet CIT Country/Territory United States Date 23/05/23 URL www.businesswire.com/news/home/20230523005317/en/NCCN-Clinical-Practice-Guidelines-in-Oncology-Updated-to-Recommend-BESREMi%C2%AE-ropeginterferon-alfa-2b-njft-as-a-Preferred-Intervention-for-Polycythemia-Vera Persons John Mascarenhas Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera Media name/outlet Bluefield Daily Telegraph Country/Territory United States Date 23/05/23 URL https://www.bdtonline.com/news/nation_world/nccn-clinical-practice-guidelines-in-oncology-updated-to-recommend-besremi-ropeginterferon-alfa-2b-njft-as/article_8dbd087b-b703-5ad6-b4d3-906639695031.html Persons John Mascarenhas Title PharmaEssentia USA Corporation: NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera Media name/outlet FinanzNachrichten.de Country/Territory Germany Date 23/05/23 URL https://www.finanznachrichten.de/nachrichten-2023-05/59157835-pharmaessentia-usa-corporation-nccn-clinical-practice-guidelines-in-oncology-updated-to-recommend-besremi-ropeginterferon-alfa-2b-njft-as-a-preferr-004.htm Persons John Mascarenhas Title NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemi Media name/outlet Acrofan Date 22/05/23 URL https://us.acrofan.com/detail.php?number=830696 Persons John Mascarenhas